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SUPRAMOLECULAR MATERIALS 
Longer and safer gastric residence 
A supramolecular polymer that is stable in the acidic environment of the stomach but dissolves in the neutral-
pH environment of the intestines prolongs the safe retention of gastric devices. 
Vitaliy V. Khutoryanskiy 
In delivering a drug, a dosage form typically needs to pass several stages and overcome natural body-defence barriers 
before the drug molecules reach the target organ and provide a therapeutic effect. When a drug is administered orally — 
the most common and acceptable way of drug delivery — solid dosage forms such as tablets or capsules quickly pass 
through the oesophagus, and disintegrate either in the stomach or in the small or large intestines. Dosage forms 
travelling through the gastrointestinal tract will experience different transit times and environmental conditions 
(determined by the solution pH, water content, and the presence of enzymes and live bacteria, for instance; Fig. 1)1. 
Depending on the therapeutic needs and the nature of a dosage form, the drug should be released at a particular part of 
the gastrointestinal tract to be absorbed by its mucosal membranes. 
To prolong the residence of dosage forms in the stomach, rapidly swelling superporous hydrogels2, floating systems3, 
and mucoadhesive formulations4 have been proposed. However, these materials and approaches typically provide 
modest retention effects (up to several hours only). Another viable strategy to prolong gastric residence is that of devices 
designed to expand/unfold to sizes greater than 2 cm in diameter, which temporary prevents their exit through the 
pylorus5. These devices are often made from elastomeric polymers to ensure their foldability. However, the greatest 
limitation in the use of this strategy is the risk associated with potential intestinal obstruction caused by the migration of 
non-degradable large components of these devices from the stomach. Now, Giovanni Traverso, Robert Langer and 
colleagues report in Nature Materials the design of pH-responsive supramolecular gels that exhibit excellent stability and 
elasticity under the acidic conditions of the stomach, and that undergo dissolution in the less acidic conditions of the 
small and large intestines6. 
The human stomach has evolved to digest food and then to pass it to the intestine for further transformation and 
absorption of nutrients. The acidic conditions in the stomach (with pH values in the range of 1–5) are supposed to 
facilitate food digestion and deactivate some harmful microorganisms. Typically, as with ingested food, dosage forms 
taken orally are expected to reside in the stomach for up to 2 hours (the average half gastric emptying time is around 
80.5 min)7, and then to move to the small intestine1. Although the majority of drugs taken orally are expected to be 
absorbed in the intestinal sections of the gastrointestinal tract, some therapeutic areas require the dosage forms to have 
longer residence in the stomach. This is important for the treatment of some stomach disorders (such as stomach ulcer)3, 
for bariatric interventions8, and also for diagnostic purposes9. 
Traverso and co-authors developed the supramolecular gel by co-precipitating, from their aqueous mixtures, the 
synthetic polymers poly(methacrylic acid-co-ethylacetate) — a commercially available as a pharmaceutical excipient — 
and poly(acryloyl 6-aminocaproic acid) (PA6ACA) — polymerised through radical initiation of the monomer acryloyl 6-
aminocaproic acid, a product of the reaction between 6-aminocaproic acid and acryloyl chloride. The gels, which formed 
through interchain hydrogen bonding, are elastic and exhibit enteric properties, that is, they can be re-dissolved in neutral 
or alkali environments as a result of the deprotonation of carboxylic groups and the dissociation of hydrogen bonds. The 
authors used the gels as key building blocks in combination with biodegradable polycaprolactone to fabricate prototype 
gastric-retentive devices, which were designed in the form of a ring that can be folded, inserted into oral gelatin capsules, 
administered, and monitored radiographically in vivo. In pigs, the gelatin capsules dissolved in the stomach within 15 
minutes of ingestion, thus deploying the gastric-retentive devices in the original ring shape. Retention of the ring-shape 
devices in the stomach of pigs lasted for two to five days, but eventually led to their partial breakage (through the 
dissociation of one or two supramolecular gel linkers) and successful passage into the intestine. A less acidic 
environment in the intestine caused further dissolution of the supramolecular gel linkers and subsequent disintegration of 
the device into smaller pieces that safely passaged through the lower gastrointestinal tract without causing any 
obstruction (Fig. 2).  
Fabrication of gastric-retentive devices with improved safety profiles using new materials may stimulate further research 
and hopefully lead to the clinical translation of the materials and associated technology. Moreover, the concept of using 
foldable, expandable and degradable devices could also be beneficial for urinary bladder-retentive devices and similar 
technology in other therapeutic areas. 
Vitaliy V. Khutoryanskiy is at the School of Pharmacy, University of Reading, Berkshire RG6 6AD, UK. 
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 Figure 1 | Morphology of the human gastrointestinal tract, and pH values and transit times at different parts of the tract. Figure 
adapted with permission from ref. 1, © Elsevier. 
 
 
 
 
 
Figure 2 | A prototype gastric retentive device. a,b, Photograph of the device (a) and schematic of  its administration and safe 
passage through a pig’s gastrointestinal tract (b). Figure adapted from ref. 6, Nature Publishing Group. 
